Iradimed earnings date
Iradimed (46K) Q3 2026 Earnings Report
DE:46K Q3 2026 EPS Results
- Actual EPS
- EUR 0.49
- Consensus EPS
- EUR 0.49
- Beat/Miss
- Met expectations
- One Year Ago EPS
- EUR 0.42
DE:46K Q3 2026 Revenue Results
- Actual Revenue
- EUR 21.53M
- Expected Revenue
- EUR 20.88M
- Beat/Miss
- Beat by +EUR 654.76K
- YoY Revenue Growth
- +14.15%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 10/30/2026
- Time
- Before Open
- Conference Call
- Friday, October 30, 2026
Iradimed's next earnings date is estimated for February 4, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was strongly positive, supported by record revenue and bookings, rapid adoption of the 3870 pump, strong monitor performance, improving manufacturing efficiencies, robust cash generation and an optimistic 2027 growth outlook. The main challenges were the reduced full-year guidance, the need to moderate the production ramp to protect quality, remaining 3870 production inefficiencies, higher taxes and expenses, and the fact that 3870 disposable pull-through has not yet begun materially.
For the fourth quarter, IRadimed expects revenue of $25 million to $26.5 million, GAAP diluted earnings per share of $0.53 to $0.57, non-GAAP diluted earnings per share of $0.57 to $0.61, an effective tax rate of approximately 24% to 25%, gross margin improvement from 76%, and another 50-plus percent increase in 3870 pump output and revenue to about 500 units; for full year 2026, it expects revenue of $91.7 million to $93.2 million, GAAP diluted earnings per share of $1.90 to $1.94, non-GAAP diluted earnings per share of $2.06 to $2.10, approximately $0.6 million of stock-based compensation expense, net of tax, for the fourth quarter and about $2.5 million for the full year; for 2027, production is expected to go from 500 to 560, 570, pump sales are planned at about 2,000 to 2,500 3870s per year, revenue growth is expected to be upper teens of growth, or 15%, 16%, 17% growth, and gross margin could return to historical 77%, 78% and even potentially even better as time goes on.
- Record Quarterly Revenue and EarningsThird-quarter revenue reached a record $24.2 million, up 14% from $21.2 million in Q3 2025 and up 18% sequentially from $20.5 million in Q2. GAAP diluted earnings per share were $0.51 and non-GAAP diluted earnings per share were $0.55, compared with $0.43 and $0.47, respectively, a year earlier.
- Strong 3870 MR IV Pump Launch and Production RampThe company produced over 400 3870 systems during Q3, with production increasing by over 125% from Q2. More than 300 pumps were shipped in Q3, and management expects Q4 3870 pump revenue and output to increase by another 50-plus percent, approaching approximately 500 units.
- Record Bookings and Growing BacklogThe sales team booked record numbers of both the 3880 monitor and 3870 pump during Q3. Management reported a comfortable Q4 backlog for 3870 pumps, 3880 monitor systems and FMD systems, supporting confidence in forecasting Q4 revenue.
- Monitor Demand Remains StrongMRI-compatible patient vital signs monitoring revenue was $8.0 million, up 17% year-over-year. Monitor bookings reached a record in Q3 for the second consecutive quarter after weak bookings in Q1, and management said monitor sales are strong and growing.
- Broad-Based Revenue Growth Across Products and Recurring RevenuePump revenue was $8.7 million, up 4% year-over-year; FMD revenue was $0.5 million, up 28%; disposables revenue grew 21% to $5.0 million; amortization of extended maintenance agreements grew 31% to $0.8 million; and services and other revenue grew 42% to $1.2 million.
- International Revenue GrowthInternational revenue grew 45% year-over-year to $4.5 million in Q3, while domestic revenue grew 9% to $19.7 million. For the first nine months, international revenue rose 37% to $12.2 million.
- Improving Manufacturing Efficiencies and Gross Margin OutlookManagement said manufacturing teams are progressing along the 3870 learning curve and beginning to realize anticipated efficiencies. Gross margin was reported at 76% for the quarter, and the company expects gross margin to continue improving in Q4. Management said it could return to historical gross margins of 77% to 78% and potentially higher in early 2027 as volumes increase and quad-system ASPs contribute.
- Operating Income and Cash Flow ExpansionOperating income was $8.1 million, or 34% of revenue, up 19% from $6.8 million, or 32% of revenue, in Q3 2025. Nine-month operating cash flow was $21.2 million, up 12%, while quarterly non-GAAP free cash flow was $6.8 million versus $5.7 million a year earlier and nine-month non-GAAP free cash flow was $20.1 million versus $11.0 million.
- Strong Balance Sheet and Lower Capital ExpendituresCash and cash equivalents ended the quarter at $63.3 million, compared with $59.1 million at the end of Q2 and $51.2 million at year-end. Third-quarter capital expenditures were $0.2 million and nine-month capital expenditures were $1.1 million, down from $8.0 million in the prior-year period, which included construction of the new corporate office and manufacturing facility.
- Large 3870 Replacement Opportunity and Higher ASPThe company estimates nearly 6,400 older 3860/3861 pump channels in the U.S. market that are more than five years old. Approximately 70% of replacement orders for two older channels involve one new quad stack, translating the installed base into an opportunity of more than 10,000 3870 units. The company plans to sell about 2,000 to 2,500 3870s per year, with an ASP of nearly $25,000 per channel, representing a 23% to 25% increase from the older 3860 ASP.
- Greenfield Customer Adoption of the 3870The company has received orders from facilities that previously did not favor the 3860 or had not purchased it. Management attributed the appeal of the 3870 to its updated user interface, sensors, intelligence and on-screen animations designed to help users operate the pump.
- Expanded Monitor Remote-Control CapabilityIRadimed expanded the monitor's remote capability by enabling two additional remotes elsewhere in a hospital through the facility's wired Ethernet network. Management said the enhancement fits the needs of a significant number of hospitals and provides additional selling points for the monitor.
- Positive 2027 Growth OutlookAlthough formal 2027 guidance was not provided, management said it expects upper-teens growth in 2027, described as approximately 15%, 16% or 17% growth, and expects to resume breaking quarterly revenue records. Management also expects new-pump disposable usage to begin compounding throughout 2027 as customers increasingly use the installed pumps.
- Dividend DeclarationThe Board declared a regular quarterly cash dividend of $0.20 per share, payable November 27, 2026, to stockholders of record as of November 13, 2026.
DE:46K Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 04, 2027 | 2026 (Q4) | 0.53- | 0.48 | ― | ― |
| Oct 30, 2026 | 2026 (Q3) | 0.490.49 | 0.42 | 17.02% (+0.07) | |
| Jul 31, 2026 | 2026 (Q2) | 0.390.41 | 0.44 | -6.12% (-0.03) | |
| May 01, 2026 | 2026 (Q1) | 0.400.44 | 0.37 | 16.67% (+0.06) | |
| Feb 10, 2026 | 2025 (Q4) | 0.430.48 | 0.39 | 22.73% (+0.09) | |
| Nov 03, 2025 | 2025 (Q3) | 0.400.42 | 0.38 | 9.30% (+0.04) | |
| Aug 01, 2025 | 2025 (Q2) | 0.390.44 | 0.37 | 16.67% (+0.06) | |
| May 05, 2025 | 2025 (Q1) | 0.360.37 | 0.32 | 16.67% (+0.05) | |
| Feb 13, 2025 | 2024 (Q4) | 0.390.39 | 0.35 | 12.82% (+0.04) | |
| Oct 31, 2024 | 2024 (Q3) | 0.360.38 | 0.38 | 0.00% (+0.00) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

